Vivus shares dive following 3rd-quarter report

NEW YORK (AP) -- Shares of Vivus Inc. fell sharply Wednesday after the drug developer reported a third-quarter loss, though analysts maintained their focus on the company's potential obesity treatment Qnexa. The stock shed 90 cents, or 11.2 percent, to $7.15 in afternoon trading. Shares have traded between $2.72 and $12.88 over the last 52 weeks.On Tuesday, Vivus announced a quarterly loss of $21.1 million, or 30 cents per share, compared with profit of $266,000, or less than a penny per share, during the same period a year prior. Revenue plunged to $4.4 million from $25.5 million recorded in the 2008 quarter, when the company reported deferred revenue from the sale of its spray-on hot flash treatment Evamist.Analysts polled by Thomson Reuters expected a loss of 31 cents per share on revenue of $5.3 million.During the latest quarter, sales of the erectile dysfunction product Muse fell 2 percent to $4.3 million.The company said it remains on track to ask for Food and Drug Administration approval of Qnexa by the end of 2009. The development of Qnexa is part of a surge in obesity treatment development from the biotechnology sector. If approved, Qnexa would likely compete with other treatments including Arena Pharmaceuticals Inc.'s lorcaserin and Orexigen Therapeutics Inc.'s Contrave.Vivus had cash, cash equivalents and available-for-sale securities of $226.9 million as of Sept. 30."Vivus is developing what we believe to be the best-in-class agent in an exciting new category of agents for the treatment of obesity," said Merriman Curhan Ford analyst Michael G. King Jr. in a note to investors. "A new era of pharmacologic therapy for obesity has arrived, and the category possesses blockbuster potential."He reaffirmed a "Buy" rating on the stock.Meanwhile, JMP Securities analyst Jason N. Butler reaffirmed...
Click here to read the whole Article (external link)

Orexigen 3rd-quarter loss narrows on lower costs

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009

SAN DIEGO, Nov. 4, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - News) today announced it will report third quarter 2009 financial results after the NASDAQ Global Market closes on Monday, November 9, 2009. The next morning, November 10, 2009, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results for the third quarter 2009 and to provide a business and financial update. The conference call may be accessed by dialing 888.452.4024 for domestic callers and 719.325.2385 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2009 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing or...
Click here to read the whole Article (external link)

Q3 2009 Arena Pharmaceuticals Earnings Release - After Market Close

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Show all filings for ARENA PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for ARENA PHARMACEUTICALS INC 10-Nov-2009Results of Operations and Financial Condition, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information...
Click here to read the whole Article (external link)

Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - News) today reported financial results for the third quarter ended September 30, 2009. Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share."The successful completion of the lorcaserin pivotal program in the third quarter was a critical milestone for Arena," stated Jack Lief, Arena's President and Chief Executive Officer. "The positive results were received with support and enthusiasm at The Obesity Society's annual meeting last month. Participating physicians shared with us three clear themes: the pressing need for new weight management treatments, the paramount importance of safety in treating overweight and obese patients, and that weight reduction should translate into improvements in cardiometabolic health. If approved, the unique combination of efficacy, safety and tolerability positions lorcaserin as first-line therapy."As expected, research and development expenses declined significantly to $22.1 million in the third quarter of 2009 from $47.5 million in the third quarter of 200...
Click here to read the whole Article (external link)

ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. This discussion and analysis should be read in conjunction with our financial statements and notes thereto included in this quarterly report on Form 10-Q, or Quarterly Report, and the audited consolidated financial statements and notes thereto included in our annual report on Form 10-K for the year ended December 31, 2008, or 2008 Annual Report, as filed with the Securities and Exchange Commission, or SEC. Operating results are not necessarily indicative of results that may occur in future periods. This Quarterly Report includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "may," "will," "intend," "plan," "believe," "anticipate," "expect," "estimate," "predict," "potential," "continue," "likely," or "opportunity," the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Readers of this Quarterly Report are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the time this Quarterly Report was filed with the SEC. These forward-looking statements are based largely on our expectations and projections about future events and future trends affecting our business, and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, w...
Click here to read the whole Article (external link)

Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript

Arena Pharmaceuticals Inc. (ARNA) Q3 2009 Earnings Call November 10, 2009; 08:30 am ET Executives Robert Hoffman - Vice President of Finance & Chief Financial Officer Jack Lief - President & Chief Executive Officer Christy Anderson - Vice President of Clinical Development Dominic Behan - Senior Vice President & Chief Scientific Officer Bill Shanahan - Vice President & Chief Medical Officer Analysts Craig Gordon - Cohen & Co. Terence Flynn - Lazard Capital Markets Jon Lecroy - Hapoalim Alan Carr - Needham & Co. Jason Zhang - BMO Capital Markets Jeff Elliott - UBS Carol Werther - Summer Street Research Presentation Operator Good day everyone and welcome to Arena Pharmaceuticals’ third quarter 2009 financial results conference call. This call is being recorded. At this time, for opening remarks and introductions, I’d now like to turn the call over to Arena’s Vice President, Finance and Chief Financial Officer, Mr. Robert Hoffman. Mr. Hoffman; please go ahead, sir. Robert Hoffman Thank you, Jennifer. Good morning and welcome to Arena Pharmaceuticals third quarter 2009 financial results conference call. I’m Robert Hoffman, Arena’s Vice President of Finance and Chief Financial Officer. Joining me on the call today are Jack Lief, our President and CEO; and Christy Anderson, our Vice President of Clinical Development. Also available to address your questions are Dominic Behan, our Senior Vice President and Chief Scientific Officer, and Bill Shanahan, our Vice President and Chief Medical Officer. Before we begin, I’d like to point out that we’ll be making numerous forward-looking statements during this ...
Click here to read the whole Article (external link)

Arena Pharma narrows 3Q loss as testing costs fall

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

ARENA PHARMACEUTICALS INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)